Table 5.

Performance of Wider system susceptibility testing with gram-positive isolatesa

Antimicrobial agentb% MICs obtained with Wider system within indicated log2 reference MICs:% Essential agreement% Errors
>−2−2−10+1+2>+2miMVM
Penicillin (81)b,c,d,e 1.27.48.062.010.33.41.280.40.00.00.0
Ampicillin (22)d 0.00.09.181.89.10.00.0100.00.00.00.0
Oxacillin (53)c 0.01.93.788.63.71.90.096.20.03.40.0
Cefazolin (53)c 0.05.613.279.20.01.80.092.4NANANA
Cefotaxime (59)c,e 0.03.455.933.95.11.70.094.9NANANA
Vancomycin (81)c,d,e 0.00.02.570.427.20.00.0100.00.00.00.0
Teicoplanin (81)c,d,e 0.00.06.281.57.44.90.095.11.30.00.0
Gentamicin (53)c 7.50.00.090.51.80.00.092.40.00.09.1
Amikacin (53)c 0.09.41.888.35.60.00.090.5NANANA
Gentamicin HLAR (22)d 0.00.00.0100.00.00.00.0100.00.00.00.0
Streptomycin HLAR (22)d 0.00.00.0100.00.00.00.0100.00.00.00.0
Erythromycin (81)c,d,e 2.50.02.595.10.00.00.097.5NANANA
Clindamycin (59)c,e 0.01.71.796.60.00.00.098.31.70.00.0
Ciprofloxacin (81)c,d,e 0.00.02.587.67.42.50.097.51.22.20.0
SXT (59)c,e 0.00.01.796.61.70.00.0100.00.00.00.0
Tetracycline (75)c,d 0.00.00.073.61.35.30.094.60.02.40.0
 Total (935)0.71.96.982.56.01.70.195.50.41.60.6
  • a Abbreviations: NA, not applicable; SXT, trimethoprim-sulfamethoxazole; mi, minor error; M, major error; VM, very major error; HLRA, high-level aminoglycoside resistance.

  • b Values in parentheses are the number of organism-antimicrobial agent combinations tested.

  • c Staphylococcus and Micrococcus.

  • d Enterococcus.

  • e β-Hemolytic streptococci.